K. Kim McCleary, also known as K. Kimberly Kenney, is the Managing Director of FasterCures, a Center of the Milken Institute that works to speed and improve the medical research system.
From 1991 until June 2013, she served as President and CEO of the Chronic Fatigue and Immune Dysfunction Syndrome Association of America, often abbreviated CFIDS Association of America or CAA, (now the Solve ME/CFS Initiative). During her tenure the Association was instrumental in developing the 1998 policy ruling for the Social Security Administration that first recognized CFS as a disabling condition; fought to create CFSAC, the ME/CFS advisory committee to the Health and Human Services Department; exposed the CDC's misappropriation of $12.9 millions of dollars designated for CFS program and worked with the agency and members of Congress, including, Senator Harry Reid, to restore those funds to research and awareness activities; helped launch the Research Institute Without Walls with Dr. Suzanne Vernon; organized lobby days; and led numerous fundraising and public awareness campaigns.
As with so many of the illness's most dedicated champions, McCleary has a family member who has ME/CFS.
Awards[edit | edit source]
- 2001, Special Service Award awarded by International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (IACFS/ME)
CFSAC testimony[edit | edit source]
- May 2009, Written testimony
- Oct 2009, Written testimony
- May 2010, Written testimony
- Oct 2010, Public testimony
- May 2011, Written testimony
Articles[edit | edit source]
Notable studies[edit | edit source]
- 2014, No association found between the detection of either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus and chronic fatigue syndrome in a blinded, multi-site, prospective study by the establishment and use of the SolveCFS BioBank - (Full Text)
Learn more[edit | edit source]
- Apr 24, 2013, "End of an Era: Kim McCleary Steps Down After 22 Years at the Helm of the CFIDS Association of America (CAA)," by Cort Johnson
See also[edit | edit source]
Online presence[edit | edit source]
References[edit | edit source]
- "IACFS/ME Awardees". IACFS/ME. Retrieved April 23, 2020.
- Irlbeck, David M.; Vernon, Suzanne D.; McCleary, K. Kimberly; Bateman, Lucinda; Klimas, Nancy G.; Lapp, Charles W.; Peterson, Daniel L.; Brown, James R.; Remlinger, Katja S.; Wilfret, David A.; Gerondelis, Peter (2014). "No association found between the detection of either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus and chronic fatigue syndrome in a blinded, multi-site, prospective study by the establishment and use of the SolveCFS BioBank". BMC Research Notes. 7: 461. doi:10.1186/1756-0500-7-461.
Chronic Fatigue and Immune Dysfunction Syndrome (CFIDS) - Chronic Fatigue and Immune Dysfunction Syndrome is another term for Chronic Fatigue Syndrome, but one which emphasizes the immunological aspects of the disease. Popular in the 1990s, this term has apparently fallen into disuse.
Chronic Fatigue Syndrome Advisory Committee (CFSAC) - (sometimes pronounced SIF-SACK) A US government advisory council that met twice per year, covering current topics related to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Meetings usually lasted for two days and the results were presented to the Secretary of Health and Human Services (HHS). After 15 years, on September 5, 2018, CFSAC's charter was not renewed by the Department of HHS, effectively dissolving the committee without notice or warning.
blinded trial A clinical trial is blinded if either the participants or the researchers don't know which treatment group they are allocated to until after the results are interpreted. (Learn more: www.nottingham.ac.uk)